Compare ONC & HAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONC | HAL |
|---|---|---|
| Founded | 2010 | 1919 |
| Country | Switzerland | United States |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 28.5B |
| IPO Year | N/A | 2006 |
| Metric | ONC | HAL |
|---|---|---|
| Price | $276.64 | $36.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 16 |
| Target Price | ★ $377.91 | $34.25 |
| AVG Volume (30 Days) | 242.5K | ★ 13.5M |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.84% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | N/A | ★ $17,973,000,000.00 |
| Revenue This Year | $759.19 | N/A |
| Revenue Next Year | $14.51 | $3.74 |
| P/E Ratio | $614.06 | ★ $45.45 |
| Revenue Growth | N/A | ★ 22.47 |
| 52 Week Low | $196.53 | $18.72 |
| 52 Week High | $385.22 | $37.27 |
| Indicator | ONC | HAL |
|---|---|---|
| Relative Strength Index (RSI) | 28.89 | 58.88 |
| Support Level | $239.25 | $33.20 |
| Resistance Level | $284.51 | $37.03 |
| Average True Range (ATR) | 7.11 | 1.09 |
| MACD | -2.02 | 0.10 |
| Stochastic Oscillator | 1.35 | 76.17 |
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Halliburton is North America's largest oilfield-services company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. Halliburton's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been honed over a century of operations.